CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage
biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular
diseases, will report fourth quarter and full-year 2017 financial results after the Nasdaq Global Market closes on Thursday, March
1, 2018. Subsequently, at 4:30 p.m. Eastern Time, the Company will host a conference call to discuss its fourth quarter and
full-year 2017 financial results and to provide a corporate update.
The conference call may be accessed by dialing 844-534-7313 for domestic callers and +1-574-990-1451 for
international callers. The passcode for the call is 7396848. Please specify to the operator that you would like to join the
"Sarepta Fourth Quarter and Full-Year 2017 Earnings Call". The conference call will be webcast live under the investor relations
section of Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days. Please connect to
Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be
necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of
precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the
development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please
visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our
website at www.sarepta.com. We encourage investors and potential investors to consult our
website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
iestepan@sarepta.com
or
W2O Group
Brian Reid, 212-257-6725
breid@w2ogroup.com
